Vor Biopharma (VOR) Free Cash Flow (2020 - 2026)
Vor Biopharma (VOR) posted quarterly Free Cash Flow of -$38.3 million for Q1 2026, down 23.27% year-over-year from -$49.9 million in Q1 2025, and down 65.67% quarter-over-quarter from -$23.1 million in Q4 2025.
Vor Biopharma (VOR) Free Cash Flow (2020 - 2026) Analysis & Trends
Vor Biopharma (VOR) has reported Free Cash Flow for 7 consecutive years, with -$38.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 23.27% year-over-year to -$38.3 million; the TTM figure through Mar 2026 stood at -$150.9 million (down 50.32% YoY), while the FY2025 annual figure was -$143.7 million, down 43.81% from the prior year.
- Free Cash Flow slipped to -$38.3 million in Q1 2026 per VOR's latest filing, from -$23.1 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$11.1 million in Q3 2022 and bottomed at -$53.9 million in Q3 2025.
- Historically, Free Cash Flow has averaged -$27.5 million across 5 years, with a median of -$24.6 million in 2023.
- Annual changes were most pronounced in 2022 — Free Cash Flow jumped 44.22% — and 2023, when it sank 155.18%.
- Vor Biopharma's Free Cash Flow stood at -$18.3 million in 2022, then dropped by 26.24% to -$23.1 million in 2023, then retreated by 4.31% to -$24.1 million in 2024, then gained by 4.23% to -$23.1 million in 2025, then slumped by 65.67% to -$38.3 million in 2026.
- Business Quant data shows VOR's Free Cash Flow at -$38.3 million in Q1 2026, -$23.1 million in Q4 2025, and -$53.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Vor Biopharma | 1.36 Bn | 1.36 Bn | - | -25.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.50 Mn |
| Jun 30, 2026 | -25.50 Mn |
| Mar 31, 2026 | -38.29 Mn |
| Mar 31, 2026 | -38.29 Mn |
| Dec 31, 2025 | -23.12 Mn |
| Dec 31, 2025 | -23.12 Mn |
| Sep 30, 2025 | -53.91 Mn |
| Sep 30, 2025 | -53.91 Mn |
| Jun 30, 2025 | -35.57 Mn |
| Jun 30, 2025 | -35.57 Mn |
| Mar 31, 2025 | -31.07 Mn |
| Mar 31, 2025 | -31.07 Mn |
| Dec 31, 2024 | -24.14 Mn |
| Dec 31, 2024 | -24.14 Mn |
| Sep 30, 2024 | -23.32 Mn |
| Sep 30, 2024 | -23.32 Mn |
| Jun 30, 2024 | -21.86 Mn |
| Jun 30, 2024 | -21.86 Mn |
| Mar 31, 2024 | -30.58 Mn |
| Mar 31, 2024 | -30.58 Mn |